AcelRx Pharma (ACRX) to Present Data from Phase 3 SAP302 Study of ARX-04 as Pain Treatment
Go back to AcelRx Pharma (ACRX) to Present Data from Phase 3 SAP302 Study of ARX-04 as Pain Treatment| ACELRX PHARMA (NASDAQ: ACRX) | Delayed: 0.86 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.86 | 52 Week High | $5.88 | |||
| Open | $0.86 | 52 Week Low | $2.40 | |||
| Day High | $0.86 | P/E | N/A | |||
| Day Low | $0.86 | EPS | $-1.50 | |||
| Volume | 8 | |||||
